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Abstract.  
Ca
2+
 signals are central to the stimulation of insulin secretion from pancreatic β-cells by glucose and 
other agents, including glucagon-like peptide-1 (GLP-1). Whilst Ca
2+
 influx through voltage-gated 
Ca
2+
 channels on the plasma membrane is a key trigger for glucose-stimulated secretion, mobilization 
of Ca
2+
 from acidic stores has been implicated in the control of more localised Ca
2+
 changes and 
membrane potential. Nicotinic acid adenine dinucleotide phosphate (NAADP), generated in β-cells in 
response to high glucose, is a potent mobilizer of these stores, and has been proposed to act through 
two pore channels (TPC1 and TPC2, murine gene names Tpcn1 and Tpcn2). Whilst the role of TPC1 
in the control of Ca
2+
 mobilization and insulin secretion was recently confirmed, conflicting data exist 
for TPC2. Here, we used the selective and efficient deleter strain, Ins1Cre to achieve β-cell selective 
deletion of the Tpcn2 gene in mice. βTpcn2 KO mice displayed normal intraperitoneal and oral 
glucose tolerance, and glucose-stimulated Ca
2+
 dynamics and insulin secretion from islets were 
similarly normal. GLP-1-induced Ca
2+
 increases involved an increase in oscillation frequency from 
4.35 to 4.84 per minute (p=0.04) at 8 mM glucose, and this increase was unaffected by the absence of 
Tpcn2. The current data thus indicate that TPC2 is not absolutely required for normal glucose- or 
incretin-stimulated insulin secretion from the β-cell. Our findings suggest that TPC1, whose 
expression tended to increase in Tpcn2 null islets, might be sufficient to support normal Ca
2+
 
dynamics in response to stimulation by nutrients or incretins. 
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Introduction 
The pancreatic islet β-cell is an important model for the study of fuel sensing and stimulus-secretion 
coupling [1, 2]. Derangement of normal β-cell function [3], as well as a decrease in overall β-cell 
mass [4, 5], underlie insulin deficiency in type 2 diabetes [1, 6, 7] a disease which now affects more 
than 8 % of the adult population worldwide [8]. 
Classically, elevated blood glucose levels are believed to stimulate insulin secretion through an 
increased cytosolic ATP:ADP ratio [9, 10] leading to closure of ATP-sensitive K
+ 
channels (KATP) 
[11] and enhanced Ca
2+
 influx through voltage-dependent Ca
2+ 
channels (VDCCs). Whilst substantial 
pharmacological [11] and genetic [12, 13] evidence supports this model, it is undoubtedly incomplete, 
not least because deletion of KATP channel subunits (SUR1/ABCC8 and Kir6.2/KCNJ11) does not 
render β-cells wholly glucose-unresponsive [14, 15]. Indeed, it is increasingly accepted that an 
integration of nutrient, neurotransmitter and hormonal signals is necessary for the induction of insulin 
release in vivo [1, 2]. 
Internal Ca
2+ 
stores, including those associated with the endoplasmic reticulum (ER) [16], and acidic 
stores, are also known to modulate intracellular free Ca
2+
 ([Ca
2+
]i) signals in β-cells [2]. Of note, 
alkalinisation of acidic stores by inhibition of the Vo-ATPase with Bafilomycin A1 impedes glucose-
induced [Ca
2+
]i responses in these cells [17, 18]. Nicotinic acid adenine dinucleotide (NAADP) is an 
important second messenger which has been implicated in the recruitment of acidic stores for the 
generation of [Ca
2+
]i signals. Produced by the endosomal/cell surface-located enzyme CD38 via a 
base exchange reaction [19], NAADP is generated in β-cells in response to glucose [20], and the 
incretin hormone glucagon-like peptide-1 (GLP-1) [21]. Whilst the latter G-protein receptor-coupled 
hormone potently stimulates insulin secretion at permissive glucose concentrations, allowing the 
development of incretin-based therapies for type 2 diabetes [22-24], the impact of GLP-1 on β-cell 
Ca
2+
 dynamics is less well established and appears to be species dependent [25-27]. 
Whilst also a matter of debate, consensus is building that one or more of the two pore channel 
subtypes (TPC) serves as the putative NAADP receptor Ca
2+
-release channel. Nevertheless, it is also 
possible that TPCs form one part of a channel complex that also includes a distinct NAADP-binding 
protein. Expressed on endo-lysosomal compartments, TPCs (gene name TPCN) have been implicated 
in the generation of NAADP-mediated Ca
2+
 signals in β- and other cells. Thus, TPC2 expression 
renders NAADP-unresponsive cells responsive [28], and expression of cell surface targeted TPCs 
allows NAADP to induce Ca
2+
 influx [29]. Furthermore, both the rodent Tpcn2 and the orthologous 
human TPCN2 gene have been identified as potential causal genes for diabetes-associated traits [30].  
Despite this body of data indicating an important role of TPC2 in Ca
2+
 signalling in β-cells, knock out 
of the Tpcn2 gene in various animal models has shown divergent effects. For example, global deletion 
of the Tpcn2 gene in the mouse through the use of a gene trap vector renders pancreatic β-cells 
unresponsive to NAADP either through use of the cell permeable analogue NAADP-AM or through 
introduction of NAADP directly through the patch pipette [17, 28]. Similarly, glucose-induced Ca
2+
 
signals are also somewhat impaired in Tpcn2
-/-
 mice, although they are not fully ablated [17]. 
Nonetheless, glucose-induced insulin secretion was barely affected and glucose tolerance was not 
abnormal in Tpcn2
-/-
 animals [17]. On the other hand, Tpcn1
-/-
 mice showed clear differences in both 
parameters [17]. Of note, although the Tpcn2
-/-
 mice used in a recent study by Wang et al. [18] 
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similarly failed to show any abnormalities in terms of responses to NAADP, the truncation in this 
allele may still enable the expression of a functional TPC2 protein [31].  
In light of these discrepancies, we have generated β-cell-specific Tpcn2 knockout mice by crossing 
animals harbouring a floxed exon of the Tpcn2 gene to knock-in mice expressing Cre recombinase at 
the endogenous Ins1 locus [32, 33]. This strategy results in efficient (~95%) recombination in β-cells 
[32, 33] (Johnston et al, unpublished results) throughout the islet. Furthermore, and in contrast to 
other currently-available insulin promoter-driven Cres, notably RIP2Cre [34-36], recombination with 
the Ins1Cre strain is not complicated either by off-target events including recombination in the brain 
[37] nor by the simultaneous ectopic expression of human growth hormone (hGH) in the β-cell.  
This approach has enabled us to further study the role of TPC2 in the β-cell whilst eliminating 
confounding effects which may result from the deletion of the Tpcn2 gene in other tissues. After 
confirming ablation of Tpcn2 expression we have used this model to determine the cell autonomous 
role of TPC2 in the β-cell, focussing on glucose homeostasis, insulin secretion and the regulation of 
Ca
2+
 dynamics by glucose and incretins.  
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2. Methods 
2.1 Animal origin and maintenance  
Mice heterozygous for the floxed allele of the Tpcn2 gene (exon 6 flanked by loxP sites) were 
obtained from the European conditional mouse mutagenesis program (EUCOMM) via MRC Harwell, 
U.K. Mice bore the “Tm1c” (http://www.mousephenotype.org/about-ikmc/eucomm-
program/eucomm-targeting-strategies) allele (Tpcn2
tm1c(EUCOMM)Hmgu
) and were crossed with Ins1Cre-
expressing animals [32]. The subsequent litters were back-crossed to generate Tpcn2
fl/fl
:Ins1Cre
+/-
 
(referred to as ‘KO’) and Tpcn2fl/fl:Ins1Cre-/- (referred to as ‘control’) mice. Offspring were bred 
together to generate litters with ~50 % WT mice and ~50% β-cell specific Tpcn2-deleted mice. 
Animals bearing the Ins1Cre transgene alone displayed no abnormalities in glucose tolerance, insulin 
secretion or β-cell mass [32]. 
Animals were maintained on a C57/BL6 background and 2 to 4 mice were housed per individually-
ventilated cage in a pathogen-free facility. Mice were kept under a 12 h light/dark cycle and fed a 
regular chow diet (Lillico Biotechnology). All in vivo experiments were performed on male mice and 
islets were isolated from an equal number of male and female mice. All animal experiments were 
approved by the UK Home Office under the Animals (Scientific Procedures) Act 1986 (PPL 
70/7349). 
2.2 qRT-PCR  
Approximately 100 freshly isolated islets were used for RNA extraction using TRIzol reagent 
(Invitrogen) and cDNA was generated using a high capacity reverse transcription kit (Applied 
Biosystems) according to the manufacturer’s instructions. SYBR Green qRT-PCR was performed as 
previously described (REF) and β-Actin was used as the reference gene.  
2.3 Glucose Tolerance Tests 
Mice were fasted overnight before i.p. injection or oral gavage of 30% glucose in water to a dose of 
either 1g/kg or 3g/kg. Blood was sampled from the tail vein at 0, 15, 30, 60 and 120 min and 
glycaemia measured using an automatic glucometer (Accu-chek, Roche). 
2.4 Insulin Secretion 
Islets were isolated by collagenase dissociation as described previously [38] and ~50 islets were 
perifused with Krebs-HEPES buffer (in mM, 130 NaCl, 3.6 KCl, 0.5 NaH2PO4, 2 NaHCO3, 1.5 
CaCl2, 1.2 MgCl2, 3 D-glucose, 10 HEPES, 0.5 MgSO4, pH 7.4 substituted with 0.1% bovine serum 
albumin) at a rate of 500 µl min
-1
 at 37 °C in a custom-built chamber. Perifusate was collected in 30 s 
intervals. Islets were primed with Krebs medium containing 3 mM glucose for 30 minutes prior to the 
experiment and glucose was increased to 16.9 mM 2 min. after the initial collection. Islets were then 
frozen in 10 ml acidic ethanol (1.5% 1M HCl, 75% EtOH, 0.1% Triton X-100) until assayed for total 
insulin content. The latter samples were diluted 1:100 whilst secreted insulin samples were assayed 
undiluted using an HTRF insulin assay kit (Cisbio assays) and a PHERAstar reader (BMG), following 
the manufacturer's guidelines. 
2.5 Calcium imaging  
Experiments were performed essentially as previously described [26]. In brief, islets were loaded with 
10 μM Fluo-8 AM (Abcam) dissolved in DMSO (0.01 % wt/vol) in Krebs-HEPES buffer for 45 
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minutes at 37 °C. Islets were visualised using a Zeiss Axiovert confocal microscope and perifused 
continuously at 34-36 °C with Krebs-HEPES buffer containing relevant concentrations of glucose and 
GLP-1. Fluo-8 was excited with a 491 nm laser and emitted light collected at 525 nm. Volocity
TM
 
software (Perkin-Elmer) was used for imaging and analysis. Traces were normalised to the initial 
fluorescence (F/F0). 
2.6 Statistics 
Data were analysed using GraphPad PRISM 6.0 software and significance was tested using unpaired 
Student’s two-tailed t-tests with Bonferroni post-tests for multiple comparisons, or two-way ANOVA 
as indicated. P<0.05 was considered significant and errors signify mean ± SEM. 
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3. Results 
3.1 Unaltered glucose tolerance after targeted deletion of Tpcn2 from β-cells.  
To delete TPC2 specifically from the pancreatic β-cell, mice bearing alleles of the Tpcn2 gene with 
loxP sites flanking exon 6 were crossed to mice bearing the Ins1Cre transgene [32]. In the first 
instance, we confirmed the Cre excision event by PCR. Primers flanking the loxP sites were expected 
to generate a 1055 bp fragment in the control islets, and a smaller fragment of 215 bps in the KO 
islets, after the excision event has taken place. The corresponding bands can be seen in Figure 1B. 
Secondly, we confirmed knock down of the expression of Tpcn2 by qRT-PCR. Relative expression of 
the Tpcn2 transcript from KO islets was decreased to ~50% of control levels. This reduction is 
compatible with essentially complete deletion from β-cells, assuming a β- : α-cell ratio of ~3:1 [39] 
and a ratio of Tpcn2 mRNA of 1:3 in β- : α-cells [40]. Tpcn1 mRNA levels showed a slight tendency 
towards an increase in Tpcn2 null islets (p= 0.147, Fig. 1C) 
βTpcn2 KO mice were indistinguishable from littermate control animals by visual inspection, and 
displayed normal growth and weight changes (Fig. 1D). Glucose tolerance was investigated in these 
mice by both intraperitoneal (IPGTT) and oral (OGTT) administration of the sugar, the latter allowing 
exploration of the incretin effect on insulin secretion. Mice underwent IPGTTs at 8-12 weeks, and 
then again at 16-20 weeks of age by administration of 1 g/kg glucose. Whilst a small decrease in 
glucose tolerance was observed between the younger and older mice, no significant differences were 
observed between the βTpcn2 KO mice and their littermate controls in either age group (Fig. 2A, B). 
Similarly, no significant difference between genotypes was observed during either OGTT at 12-16 
weeks (performed using a higher concentration of 3 g/kg glucose) or at 20-24 weeks of age (Fig. 2B, 
C).  
3.2 Normal glucose-induced Ca
2+
 dynamics and insulin secretion in βTpcn2 KO mouse islets 
Having demonstrated a lack of any effect of β-cell selective TPC2 ablation on glucose tolerance in 
vivo, where compensatory effects might conceivably obscure changes in β-cell glucose 
responsiveness, we performed studies using islets ex vivo to determine whether a more subtle role of 
TPC2 deletion might be unmasked. The effect of TPC2 deletion in β-cells on Ca2+ signals was 
investigated by live fluorescence microscopy on isolated islets loaded with the Ca
2+
 indicator Fluo-8. 
Peak-plateau responses in intracellular free Ca
2+ 
([Ca
2+
]i) were generated in whole islets by the 
addition of high (17 mM) glucose after a period of exposure to low (3 mM) glucose. Regions of 
interest were drawn around the whole islet to observe the coordinated response to increased glucose. 
TPC2 deletion had no obvious effect on the above Ca
2+
 responses, after analysis of both the peak and 
the area under curve (AUC). Likewise, changes in membrane potential after high glucose treatment 
were similarly not affected by the absence of TPC2 (Sones, W and RP, results not shown, n=3). 
Insulin secretion from isolated islets was next monitored dynamically over time using a custom built 
perifusion apparatus. Insulin secretion was induced by the addition of 17 mM glucose after a period of 
exposure to low glucose (3 mM). Insulin secretion began immediately after the increase in glucose 
concentration and achieved a peak rate of secretion of approximately 0.14% of the total insulin 
content per minute. Secretion then slowed to a plateau around 0.07% of total insulin per minute. The 
absence of TPC2 from β-cells resulted in no evident change in either the peak rate of this response nor 
in the overall insulin secreted, as represented by analysis of the area under the curve. 
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3.3 Normal incretin-induced Ca
2+
 dynamics and insulin secretion in βTpcn2 KO mouse islets 
We next used the same techniques to determine whether TPC2 may contribute to incretin-regulated 
Ca
2+
 dynamics. Islets were stimulated first with 11 mM glucose and additionally with 20 nM GLP-1 
eight minutes later. Addition of the incretin at this concentration of glucose did not lead to any 
significant effect on [Ca
2+
]i in control or KO islets. However, and despite not significantly affecting 
Ca
2+
 signals, GLP-1 did induce a rapid and significant increase in the plateau of insulin secretion, 
indicating that the ability of GLP-1 to increase insulin release was via potentiation of Ca
2+
-dependent 
exocytosis but did not result from an increase in [Ca
2+
]i beyond that produced by glucose alone. TPC2 
ablation did not affect the secretory response to GLP-1, nor insulin secretion in response to 8 mM 
glucose alone, as confirmed by area under the curve analysis and measurement of peak responses. 
3.4 Subtle changes in GLP-1-induced Ca
2+
 transients during moderate glucose stimulation of βTpcn2 
KO islets are indistinguishable from control 
In an attempt to investigate a more subtle role of GLP-1 in Ca
2+
 signalling and to subsequently 
investigate the role of TPC2 in this response, we induced stable Ca
2+
 oscillations in isolated mouse 
islets by stimulating with 8 mM glucose. The resulting oscillations were variable between islets as can 
be seen in the individual example traces (Fig. 5 A, B). The oscillations were also systemic across the 
islet and not specific to individual cells or regions (Fig. 5 C). The addition of GLP-1 after glucose 
administration increased the frequency of these oscillations without prompting any recruitment of 
previously quiescent cells into activity (Fig. 5 A–C). Islets showed varying responses to GLP-1 but a 
significant number showed an increase, as can be seen by the increase in frequency shown in (Fig. 5 
D-F). However, no effect of Tpcn2 deletion on this modulation of Ca
2+
 oscillation frequency was 
observed.  
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4. DISCUSSION 
4.1 Role of TPC2 in the beta cell 
We describe here the impact on glucose homeostasis and Ca
2+
 dynamics of β-cell selective deletion of 
Tpcn2 in the mouse. Elimination of TPC2 was confirmed by demonstrating a reduction in transcript 
level compatible with a selective loss from the β-cell compartment, as expected with the use of the 
efficient and β-cell-selective Ins1Cre strain [32]. Confirmation of knockdown at the protein level was 
not possible since commercially available antibodies proved to be non-specific in our hands (results 
not shown). 
The use of pharmacological agents (e.g. Bafilomycin A1) to alkalinise this compartment, or others 
(GPN) to osmotically destabilise it, have provided evidence for the importance of the acidic 
compartment as a Ca
2+
 store involved in β-cell stimulus secretion coupling [41] as well as in other cell 
types including neuronal [42] and smooth muscle [43] cells. The specific role for NAADP in 
accessing these stores has also been shown pharmacologically using competitive inhibition of 
NAADP-sensing with the putative NAADP-receptor antagonist Ned-19 [17, 20]. The potential role of 
the two-pore channel as either a direct or indirect component of the NAADP-receptive machinery has 
also been demonstrated by several groups [44][45][46][47] including ourselves [17, 31].   
However, it should be noted that technical differences between studies mean that the current literature 
from other cells types cannot necessarily be extrapolated directly to the β-cell. Most importantly, 
pharmacological inhibition may lead to off-target effects. This is especially the case when the function 
or integrity of an entire organelle is disrupted, as in the case of Bafilomycin A1 or GPN, manoeuvres 
which have been shown to also block IP3- and cADPR-mediated signals in Jurkat T-lymphocytes [48]. 
Likewise, whole-body deletion of a gene which is expressed in other metabolically relevant tissues 
could have significant subsequent effects on islet function; the Tpcn (and particularly Tpcn2) family 
are particularly strongly expressed in hematopoetic lineages in mice (bioGPS.org) and their deletion 
from these tissues might conceivably affect innate immunity or alter inflammatory status, with 
subsequent impacts on islet and β-cell function [49].   
We therefore chose in the present study to use (1) targeted gene inactivation achieved through LoxP-
mediated recombination of floxed Tpcn2 alleles, and (2) investigations of β-cell Ca2+ responses in 
whole islets. The latter preparation provides a reliable means of studying robust and reproducible 
[Ca
2+
]i signals in the absence of changes in β-cell physiology and responsiveness which can 
accompany islet disruption [26, 27]. Although the Ca
2+
 indicator used, Fluo-8, is not partitioned 
selectively into β-cells, increases in [Ca2+]i in response to glucose (or GLP-1) are likely to be 
restricted to these cells, and a small number of δ-cells, rather than α-cells which comprise ~20% of 
the islet [26].  
Examined in this setting, loss of Tpcn2 exerted no apparent effect on Ca
2+
 signals provoked by 
nutrients or incretin. Whilst this may seem to question previous findings on Tpcn2
-/-
 mice, it should be 
emphasised that our earlier studies involved the use of isolated β-cells [17]. It is therefore possible 
that the involvement of NAADP in glucose responses may be less susceptible to deletion of Tpcn2 in 
the context of the intact islet, given the complex communication and feedback mechanisms existing 
between β-cells within the micro-organ [50].   
In contrast, and despite minimal effects of Tpcn2 deletion on glucose tolerance, glucose-evoked Ca
2+
 
responses and insulin secretion [17], responses to infused NAADP were eliminated in β-cells from 
whole body Tpcn2
-/-
 mice. The present data therefore suggest that such currents, activated by high 
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NAADP, are not required for normal Ca
2+
 oscillations in response to glucose or GLP-1 (see Fig.s 3-
5). However, we would note that the present studies did not explore the impact of NAADP in βTpcn2 
KO mouse islets and it is conceivable that these NAADP-regulated currents persisted, perhaps as a 
result of up-regulation of Tpcn1 (Fig. 1C). Alternatively, smaller currents, which cannot be readily 
detected by patch clamp electrophysiology, may be critical and contribute to local changes in 
membrane potential which regulate Ca
2+
 influx. 
It is conceivable that the tendency for increases in Tpcn1 expression after Tpcn2 deletion, as seen in 
Fig. 1 is sufficient to compensate for the absence of the latter, especially given that basal levels of 
Tpcn1 mRNA in the islet are significantly (>10-fold) higher than those of Tpcn2 [17], as also 
observed in other tissues such as liver [31]. Correspondingly, Tpcn1
-/-
 mice show marked defects in 
both glucose tolerance and in glucose-stimulated insulin secretion. Thus, it is possible that significant 
functional redundancy exists between TPC1 and TPC2 in the β-cell. Studies using mice deleted for 
Tpcn1 alone or both alleles in these cells will be necessary to test this hypothesis. 
4.2 GLP-1 and Ca
2+
 dynamics 
In the physiologically relevant setting of the perifused whole islet, we observed only rather subtle 
effects of GLP-1 on Ca
2+ 
signals induced by low, stimulatory (8 mM) concentrations of glucose (Fig. 
5). These observations are thus compatible with earlier studies [25-27] demonstrating a role for GLP-
1 in controlling Ca
2+
 dynamics in β-cells. More noticeable was the complete lack of any observable 
effect of GLP-1 on Ca
2+
 dynamics induced by both intermediate (11 mM) and elevated (17 mM) 
glucose concentrations, despite marked increases in insulin secretion under the same conditions (Figs 
4, 5). This finding suggests that at these high glucose concentrations GLP-1 principally acts by 
potentiation of glucose-induced insulin secretion and does not involve an increase in electrical activity 
or [Ca
2+
]i. However, at lower glucose concentrations (8 mM), GLP-1 elicited an increase in [Ca
2+
]i 
that likely reflects stimulation of electrical activity. Thus, the mode of action of GLP-1 differs 
depending on the glucose concentration. Importantly, elimination of Tpcn2 had no effect on GLP-1-
induced changes in Ca
2+
 dynamics or insulin secretion at any of the glucose concentrations tested, 
arguing against an absolute requirement for these channels in NAADP-mediated effects. 
4.3 Overall conclusions 
The present studies demonstrate that TPC2 is not absolutely required for normal glucose or incretin 
responses in pancreatic β-cells. The present studies also suggest that the actions of GLP-1 on insulin 
secretion occur predominantly, though not exclusively, via mechanisms which are independent of 
changes in [Ca
2+
]i. We suggest that there may be significant overlap, and therefore redundancy, 
between two pore channel subtypes (Tpcn1 and Tpcn2), allowing NAADP-dependent actions to 
persist. The importance of the NAADP-mediated Ca
2+
-release pathway may also have been somewhat 
exaggerated in previous investigations. The use here of a more sophisticated, β-cell-specific deletion 
model and in vivo analyses overcome many of these limitations.  
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Table 1. List of primers. 
qRT-PCR primers were designed to span an exon boundary in order to prevent interaction with 
genomic DNA as opposed to cDNA. Tpcn2 flox primers flank a loxP site, producing differential 
product sizes for floxed and wild type alleles. Excision event primers flank both loxP sites allowing 
for confirmation of the Cre excision event.  
 
qRT-PCR  Tpcn2  F - ATGATGAAGAAGACCCTGAAGTG  
    R - TGTGCTTCATCCTTCTCACC 
  
β-actin  F - CGAGTCGCGTCCACCC 
    R - CATCCATGGCGAACTGGTG 
 
Genotyping Tpcn2 flox F - ATTCTGGGCTGCTACTGTGG 
    R - GTTGGTCCTCCTAGGCTGTG 
  
Ins1cre  F - ATGTCCAATTTACTGACCG 
    R - CGCCGCATAACCAGTGAAAC 
  
Excision event   F - CTGCTACTGTGGGTGGTATATGG 
    R - CAATGTTATTTGAACTGATGGCGAG 
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Figure Legends 
Figure 1 
(A) Schematic of the floxed allele of Tpcn2 showing the location of loxP sites flanking exon 6 and the 
target sites of primers used in (C). (B) The excision event resulting from the cross with Ins1Cre mice 
as demonstrated by the removal of the critical region containing exon 6. (C) Relative expression of 
Tpcn2 in control (black) and β-cell-specific Tpcn2 KO (blue) islets, normalised to β-actin (Actb). 
*P<0.05 for the effect of Tpcn2 deletion. (D) Changes in the weight of control (black) and KO (blue) 
animals from 8 to 20 weeks of age.  
Figure 2 
Glucose tolerance tests of control and βTpcn2 KO mice. Glucose tolerance after intraperitoneal (ip) 
glucose injection (A,B) or oral glucose via gavage (C,D) of male mice. Mice were given 1g kg
-1
 
glucose with the exception of the 12-16-week OGTT mice (C) which were given a higher dose of 3g 
kg
-1
. Experiments were quantified by area under the curve (AUC) analysis as shown in the inset bar 
graphs and the number of mice used in each experiment is shown in white. Data are expressed as 
means ± SEM. No statistically significant differences were observed. 
Figure 3 
Glucose responsiveness of control and βTpcn2 KO islets. (A - G) Ca2+ responses to 17 mM glucose in 
control islets (blue) and β-cell specific Tpcn2 KO islets (black). Example Ca2+ responses (A, B), and 
corresponding images of basal and peak fluorescence showing the global response over the whole 
islet (C, D) where scale bars correspond to 20 µm. (E) Averaged response showing the mean ± SEM 
of Ca
2+
 traces. These data are quantified by area under curve analysis (F) and the average peak 
fluorescence (G). (H-J) Insulin secretion from isolated islets from control (black) and beta cell 
specific Tpcn2 knock-out mice (blue). (H) Insulin secreted over time shown as mean ± SEM. 
Quantification of the insulin secretion during the period from 2-32 minutes after the start of the 
experiment by total insulin secreted as a percentage of the total insulin content of the islets (I) and 
peak insulin response (J). The number of islets used for each set of experiments is shown on the bars 
in white. 
Figure 4 
Effect of GLP-1 on control and βTpcn2 KO islets (A) Average Ca2+ responses showing mean ± SEM. 
(B, C) Quantification of the area under the curve (AUC) and peak of Ca
2+
 traces. (D) Insulin secretion 
from isolated islets from control (black) and βTpcn2 KO mice (blue). (E, F) Quantification of insulin 
secretion during the period from 2-32 minutes after the start of the experiment for the 17 mM glucose-
stimulated islets, or from 10-32 minutes for the 11 mM glucose plus GLP-1-stimulated islets. The 
number of islets used for each set of experiments is shown on the bars in white. 
Figure 5 
Effect of GLP-1 on Ca
2+
 oscillations in control and βTpcn2 KO islets. (A, B) Example traces of 
control islets (blue) and β-cell-specific Tpcn2 KO islets (black), showing Ca2+ responses to 8 mM 
glucose with the addition of GLP-1. Boxes in (B) indicate regions shown in (C). (C) Example Ca
2+
 
oscillations before and after the addition of GLP-1 after the 8 mM glucose response in a KO islet. The 
Ca
2+
 signal, as observed during a single oscillation (image capture at 2 s intervals) is apparent across 
the whole islet. The increase in oscillation frequency is apparent between the upper (-GLP-1) and 
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lower (+GLP-1) traces. Scale bar = 20 µm. (D, E) Change in oscillation frequency upon GLP-1 
stimulation normalised to the rate induced by 8 mM glucose. Oscillations were counted in a five 
minute window before and after GLP-1 addition and the red dotted line indicated the average 
increase. P<0.05 for the effects of GLP-1 in each case. (F) Quantification of the increase in oscillation 
frequency, showing no significant difference between control and βTpcn2 KO islets (mean ± SEM).  
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